These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The role of the kidney in the metabolism of prostacyclin by the 15-hydroxyprostaglandin dehydrogenase pathway in vivo.
    Author: Förstermann U, Neufang B.
    Journal: Biochim Biophys Acta; 1984 May 11; 793(3):338-45. PubMed ID: 6370311.
    Abstract:
    Five different vascular beds of the cat were tested for their ability to metabolize tritium-labeled or unlabeled prostacyclin by 15-hydroxyprostaglandin dehydrogenase in vivo. Thin-layer radiochromatography with two different solvent systems was used to characterize the radioactive metabolites formed. Following the infusion of unlabeled prostacyclin, plasma levels of 6-ketoprostaglandin F1 alpha and 6,15-diketo-13,14-dihydroprostaglandin F1 alpha immunoreactivities were monitored using previously described radioimmunoassays. No important metabolism was found in the head and the hindlimb. Plasma extracts from the vascular bed of the lung (and the heart) contained only small amounts of 6,15-diketo-13,14- dihydroprostaglandin F1 alpha-like material. prostacyclin was extensively metabolized in the liver (probably by beta- and omega-oxidation), but no material similar to 6,15-diketo-13,14-dihydroprostaglandin F1 alpha was found. In renal venous blood the predominating material showed properties similar to those of 6,15-diketo-13,14-dihydroprostaglandin F1 alpha with both analytical methods. In other experiments aortic blood was collected during and after infusions of tritium-labeled prostacyclin into the postcava . Two consistent peaks were demonstrated in plasma extracts of this blood, one co-chromatographing with 6-ketoprostaglandin F1 alpha and the other one with 6,15-diketo-13,14-dihydroprostaglandin F1 alpha. In nephrectomized animals the formation of the 6,15-diketo-13,14-dihydroprostaglandin F1 alpha-like material was not significantly impaired. Similarly, no significant differences in the formation and elimination of 6,15-diketo-13,14-dihydroprostaglandin F1 alpha immunoreactivity and 6-ketoprostaglandin F1 alpha immunoreactivity were found after nephrectomy. It is concluded that, although the kidneys have a considerable capacity to metabolize prostacyclin by 15-hydroxyprostaglandin dehydrogenase, they seem to be of little importance for the overall conversion of prostacyclin via this pathway in the total circulation.
    [Abstract] [Full Text] [Related] [New Search]